Healthcare global enterprises has announced a crucial board meeting scheduled for February 17, 2026, to consider a significant fund raise proposal. The company has formally notified stock exchanges about the upcoming deliberations on equity fundraising through rights issue mechanism.

Board Meeting Details

The Board of Directors meeting has been scheduled in compliance with regulatory requirements under SEBI Listing Regulations. The company issued the intimation on February 08, 2026, to both major stock exchanges where its shares are listed.

Fund Raise Proposal

The primary agenda involves considering and approving a proposal for fund raising through the issuance of equity shares via rights issue. This mechanism allows existing shareholders to purchase additional shares at a predetermined price, typically below market value. The proposal remains subject to applicable laws and requisite regulatory and statutory approvals.

Trading Window Restrictions

In adherence to insider trading prevention protocols, HealthCare Global Enterprises has implemented a trading window closure for all designated persons. This measure ensures compliance with SEBI's Prohibition of Insider Trading Regulations, 2015.

Regulatory Compliance

The intimation has been issued pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally communicated with both NSE and BSE compliance departments, ensuring transparent disclosure to market participants.

The announcement reflects the company's commitment to maintaining regulatory compliance while exploring strategic funding options. Additional information regarding this development is available on the company's official website at hcgoncology.com.

Healthcare Global Enterprises Limited, India's largest dedicated cancer hospital network, announced its financial results for the quarter and nine months ended December 31, 2025. The company demonstrated steady performance with revenue growth and margin expansion despite seasonal challenges in the healthcare industry.

Financial Performance Overview

The company's consolidated financial results showed robust growth across key metrics for both the quarter and nine-month periods:

Management Commentary on Results

Dr. Manish Mattoo, CEO of Healthcare Global Enterprises Ltd., highlighted that the Q3 performance reflects steady execution across the network despite seasonal softness in the healthcare industry. He noted that revenues of ₹6,331 Mn were supported by balanced performance across regional clusters, demonstrating resilient demand for high-quality oncology care across medical, radiation, and surgical oncology modalities.

The quarter demonstrated the scalability of the company's model, with adjusted EBITDA margins expanding due to operating leverage. Dr. Mattoo emphasized that HCG's focused single-specialty model, anchored in integrated care delivery and tumour-board-led clinical decision-making, continues to differentiate the company in a competitive environment, supporting strong referral flows and patient trust.

Strategic Focus and Clinical Excellence

Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, outlined the company's guiding principle of delivering the right treatment the first time with a focus on patient outcomes. As a single-specialty oncology institution with a nationwide network, HCG has built a deeply integrated care model that combines:

• Advanced diagnostics and genomics
• Multi-omics and organ-specific pathology
• Tumour-board-led decision-making
• Emerging therapies such as CAR-T

The company's commitment to clinical research is reflected in HCG clinicians contributing to one of the largest bodies of oncology research from India, with regular representation at leading international forums worldwide.

Organizational Strengthening

The company has completed senior leadership augmentation across key functions including marketing, domestic sales, and international business to support the next phase of growth. This strengthening of leadership bandwidth positions HCG for continued expansion across both metro and non-metro markets in India.

About Healthcare Global Enterprises

Headquartered in Bengaluru, Healthcare Global Enterprises Ltd. operates India's largest dedicated cancer hospital network. Through its network of 25 hospitals across India and Africa, HCG provides advanced cancer care with comprehensive cancer centers offering expertise and technologies for effective diagnosis and treatment under one roof. The company also operates fertility centers under the "Milann" brand.